Literature DB >> 30451064

Physician and patient treatment decision-making in relapsing-remitting multiple sclerosis in Europe and the USA.

Hannah Brown1, Simone Gabriele1, Joanna White1.   

Abstract

OBJECTIVE: To assess factors used in treatment decision-making for relapsing-remitting multiple sclerosis in both the 5EU (UK/Germany/France/Italy/Spain) and the USA.
METHODS: Data were abstracted from the Ipsos Healthcare Global Multiple Sclerosis Therapy Monitor (data abstracted September-December, 2015-2017) a bi-annual online chart-review study of patients with multiple sclerosis.
RESULTS: Treatment choices were primarily due to efficacy for relapses while convenience factors, other than oral administration, were uncommon. Predominantly, the choice of disease modifying therapy at first line was jointly made, with patient involvement decreasing at later lines of treatment.
CONCLUSION: Relapsing-remitting multiple sclerosis patients are highly engaged in their treatment decisions, particularly early in the pathway. The majority were made jointly between the physician and patient, driven by efficacy.

Entities:  

Keywords:  RRMS; decision-making; efficacy; patient engagement; relapsing-remitting multiple sclerosis

Mesh:

Year:  2018        PMID: 30451064     DOI: 10.2217/nmt-2018-0023

Source DB:  PubMed          Journal:  Neurodegener Dis Manag        ISSN: 1758-2024


  5 in total

1.  Factors influencing patient satisfaction with the first diagnostic consultation in multiple sclerosis: a Swiss Multiple Sclerosis Registry (SMSR) study.

Authors:  Christian Philipp Kamm; L Barin; C Gobbi; C Pot; P Calabrese; A Salmen; L Achtnichts; J Kesselring; M A Puhan; V von Wyl
Journal:  J Neurol       Date:  2019-10-08       Impact factor: 4.849

2.  "I Will Respect the Autonomy of My Patient": A Scoping Review of Shared Decision Making in Multiple Sclerosis.

Authors:  Anne Christin Rahn; Alessandra Solari; Heleen Beckerman; Richard Nicholas; David Wilkie; Christoph Heesen; Andrea Giordano
Journal:  Int J MS Care       Date:  2020-12-28

3.  Patient-based benefit-risk assessment of medicines: development, refinement, and validation of a content search strategy to retrieve relevant studies.

Authors:  Hiba El Masri; Treasure M McGuire; Christine Dalais; Mieke van Driel; Helen Benham; Samantha A Hollingworth
Journal:  J Med Libr Assoc       Date:  2022-04-01

4.  Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies.

Authors:  Gavin Giovannoni; Giancarlo Comi; Kottil Rammohan; Peter Rieckmann; Fernando Dangond; Birgit Keller; Dominic Jack; Patrick Vermersch
Journal:  Adv Ther       Date:  2021-08-09       Impact factor: 4.070

5.  Patient and Neurologist Preferences in the United States for Relapsing-Remitting Multiple Sclerosis Treatments: Findings from a Discrete Choice Experiment.

Authors:  Jinender Kumar; M Janelle Cambron-Mellott; Tom Tencer; Oliver Will; deMauri S Mackie; Kathleen Beusterien
Journal:  Patient Prefer Adherence       Date:  2021-07-08       Impact factor: 2.711

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.